Abstract

Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 2

Author(s): Zur Eyal

Issue: Jul/Aug 2019 - Volume 23, Number 4

Page(s): 288-293

Download in electronic PDF format for $75

Abstract

Cutaneous leishmaniasis is the most common form of leishmaniasis with global incidence of about 1.5 million cases annually. The disease is endemic in Israel and caused by two types, leishmania major and leishmania tropica. The two types of cutaneous leishmaniasis in Israel are not life threatening, but the multiple skin lesions developed from the contaminated sand fly bites cause significant damage to the quality of life for a few months in patients with leishmania major and sometimes for more than a year in patients with leishmania tropica. Topical treatment for this localized skin disease is very attractive although only one medication is registered in Israel (15% paromomycin +12% methylbenzethonium chloride ointment), which is for the topical treatment of “leishmania major.” Two significant disadvantages characterize this topical medication, 1) relatively low efficacy and 2) significant irritation and pain, which could result in failure of the registered treatment. This article (part 2 of a 3-part article), which also includes a compounded formulation, discusses the treatment option of paromomycin sulfate liposomal gel (free of the sensitizing methylbenzethonium chloride).

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2019 Pg. 288-293	Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 2 Author(s): Zur Eyal
Sep/Oct 2019 Pg. 366-375	Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3 Author(s): Zur Eyal
May/Jun 2019 Pg. 200-207	Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1 Author(s): Zur Eyal
Jul/Aug 2004 Pg. 269-274	Current Topical Treatments in Wound Healing - Part 1 Author(s): Helmke Christopher D
Jul/Aug 2003 Pg. 266-270	Sensitization Therapy for Warts Author(s): Kuntz Rachael
May/Jun 2004 Pg. 206-209	Basics of Compounding for Cold Sores or Fever Blisters Author(s): Allen Loyd V Jr
May/Jun 2009 Pg. 262-263	PostScription: Compounding in Israel Author(s): Zur Eyal
Sep/Oct 2015 Pg. 357-365	Novel Approaches to Topical Psoriasis Therapy Author(s): Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
May/Jun 2022 Pg. 189-193	A Compendium of Compounding Agents and Formulations, Part 3: Gentamicin Sulfate and Benzoyl Peroxide Author(s): Riepl Mike
Jul/Aug 2003 Pg. 288-291	Basics of Compounding for Raynaud's Disease Author(s): Glasnapp Andrew
May/Jun 2003 Pg. 176-178	Case Report: Topical Gel for the Treatment of a Refractory Leg Ulcer Author(s): Israel Alan
Nov/Dec 2004 Pg. 472	Gentamicin Sulfate 0.2%, Misoprostol 0.0024%, and Phenytoin 5% Topical Gel Author(s): Allen Loyd V Jr
Jul/Aug 2023 Pg. 320-321	Cyclosporine Topical Gel Formulation Author(s): Allen Loyd V Jr
Sep/Oct 2020 Pg. 367-369	Topical Cholesterol/Simvastatin Gel for the Treatment of CHILD Syndrome in an Adolescent Author(s): Cho Sung Kyung, Ashworth Lisa Diggs, Goldman Shauna
Nov/Dec 2020 Pg. 482-490	Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Author(s): Teimouri Arezou, Yeung Pollen, Agu Remigius U
Mar/Apr 2019 Pg. 94-104	Topical Treatment of Primary Focal Hyperhidrosis, Part 2 Author(s): Zur Eyal
Jan/Feb 2019 Pg. 23-31	Topical Treatment of Primary Focal Hyperhidrosis, Part 1 Author(s): Zur Eyal
Nov/Dec 2011 Pg. 458-463	Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers Author(s): Zur Eyal
Nov/Dec 2012 Pg. 462-469	Recurrent Aphthous Stomatitis: Topical Treatment with Minocycline and Other Evidence-based Agents Author(s): Zur Eyal
Nov/Dec 2007 Pg. 509	Foscarnet 2.5% Topical Cream Author(s): Allen Loyd V Jr